An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders

Most research into blood-based biomarkers for neurodegenerative disorders has so far focused on Alzheimer disease. In this Review, Aarsland and colleagues give an overview of the current status of blood-based biomarkers for the non-Alzheimer disease neurodegenerative disorders.Cerebrospinal fluid an...

Teljes leírás

Elmentve itt :
Bibliográfiai részletek
Szerzők: Ashton Nicholas J.
Hye Abdul
Rajkumar Anto P.
Leuzy Antoine
Snowden Stuart
Suárez-Calvet Marc
Karikari Thomas K.
Schöll Michael
La Joie Renaud
Rabinovici Gil D.
Höglund Kina
Ballard Clive
Hortobágyi Tibor
Svenningsson Per
Blennow Kaj
Zetterberg Henrik
Aarsland Dag
Dokumentumtípus: Cikk
Megjelent: 2020
Sorozat:NATURE REVIEWS NEUROLOGY 16 No. 5
Tárgyszavak:
doi:10.1038/s41582-020-0348-0

mtmt:31456612
Online Access:http://publicatio.bibl.u-szeged.hu/22848
LEADER 02864nab a2200409 i 4500
001 publ22848
005 20221026112351.0
008 211110s2020 hu o 0|| Angol d
022 |a 1759-4758 
024 7 |a 10.1038/s41582-020-0348-0  |2 doi 
024 7 |a 31456612  |2 mtmt 
040 |a SZTE Publicatio Repozitórium  |b hun 
041 |a Angol 
100 1 |a Ashton Nicholas J. 
245 1 3 |a An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders  |h [elektronikus dokumentum] /  |c  Ashton Nicholas J. 
260 |c 2020 
300 |a 265-284 
490 0 |a NATURE REVIEWS NEUROLOGY  |v 16 No. 5 
520 3 |a Most research into blood-based biomarkers for neurodegenerative disorders has so far focused on Alzheimer disease. In this Review, Aarsland and colleagues give an overview of the current status of blood-based biomarkers for the non-Alzheimer disease neurodegenerative disorders.Cerebrospinal fluid analyses and neuroimaging can identify the underlying pathophysiology at the earliest stage of some neurodegenerative disorders, but do not have the scalability needed for population screening. Therefore, a blood-based marker for such pathophysiology would have greater utility in a primary care setting and in eligibility screening for clinical trials. Rapid advances in ultra-sensitive assays have enabled the levels of pathological proteins to be measured in blood samples, but research has been predominantly focused on Alzheimer disease (AD). Nonetheless, proteins that were identified as potential blood-based biomarkers for AD, for example, amyloid-beta, tau, phosphorylated tau and neurofilament light chain, are likely to be relevant to other neurodegenerative disorders that involve similar pathological processes and could also be useful for the differential diagnosis of clinical symptoms. This Review outlines the neuropathological, clinical, molecular imaging and cerebrospinal fluid features of the most common neurodegenerative disorders outside the AD continuum and gives an overview of the current status of blood-based biomarkers for these disorders. 
650 4 |a Klinikai orvostan 
700 0 1 |a Hye Abdul  |e aut 
700 0 1 |a Rajkumar Anto P.  |e aut 
700 0 1 |a Leuzy Antoine  |e aut 
700 0 1 |a Snowden Stuart  |e aut 
700 0 2 |a Suárez-Calvet Marc  |e aut 
700 0 2 |a Karikari Thomas K.  |e aut 
700 0 2 |a Schöll Michael  |e aut 
700 0 2 |a La Joie Renaud  |e aut 
700 0 2 |a Rabinovici Gil D.  |e aut 
700 0 2 |a Höglund Kina  |e aut 
700 0 2 |a Ballard Clive  |e aut 
700 0 2 |a Hortobágyi Tibor  |e aut 
700 0 2 |a Svenningsson Per  |e aut 
700 0 2 |a Blennow Kaj  |e aut 
700 0 2 |a Zetterberg Henrik  |e aut 
700 0 2 |a Aarsland Dag  |e aut 
856 4 0 |u http://publicatio.bibl.u-szeged.hu/22848/1/AshtonNJ2020.Anupdateonblood-basedbiomarkersfornon-Alzheimerneurodegenerativedisorders.pdf  |z Dokumentum-elérés